JP2013528174A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013528174A5 JP2013528174A5 JP2013512048A JP2013512048A JP2013528174A5 JP 2013528174 A5 JP2013528174 A5 JP 2013528174A5 JP 2013512048 A JP2013512048 A JP 2013512048A JP 2013512048 A JP2013512048 A JP 2013512048A JP 2013528174 A5 JP2013528174 A5 JP 2013528174A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkynyl
- alkenyl
- arylalkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 88
- 125000000304 alkynyl group Chemical group 0.000 claims description 84
- 125000006725 C1-C10 alkenyl group Chemical group 0.000 claims description 81
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 75
- 125000000217 alkyl group Chemical group 0.000 claims description 71
- 238000000034 method Methods 0.000 claims description 27
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 16
- 210000004881 tumor cell Anatomy 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 102000001307 androgen receptors Human genes 0.000 claims description 10
- 108010080146 androgen receptors Proteins 0.000 claims description 10
- 238000011394 anticancer treatment Methods 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 239000000816 peptidomimetic Substances 0.000 claims description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 238000000315 cryotherapy Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000001794 hormone therapy Methods 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 230000017074 necrotic cell death Effects 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- -1 n- butyl Chemical group 0.000 claims 2
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000007792 addition Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34955510P | 2010-05-28 | 2010-05-28 | |
| US61/349,555 | 2010-05-28 | ||
| PCT/US2011/038395 WO2011150360A1 (en) | 2010-05-28 | 2011-05-27 | Oligo-benzamide compounds and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016122278A Division JP6385986B2 (ja) | 2010-05-28 | 2016-06-21 | オリゴベンズアミド化合物およびそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013528174A JP2013528174A (ja) | 2013-07-08 |
| JP2013528174A5 true JP2013528174A5 (cg-RX-API-DMAC7.html) | 2014-07-10 |
Family
ID=45004429
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013512048A Pending JP2013528174A (ja) | 2010-05-28 | 2011-05-27 | オリゴベンズアミド化合物およびそれらの使用 |
| JP2016122278A Active JP6385986B2 (ja) | 2010-05-28 | 2016-06-21 | オリゴベンズアミド化合物およびそれらの使用 |
| JP2018097720A Pending JP2018131459A (ja) | 2010-05-28 | 2018-05-22 | オリゴベンズアミド化合物およびそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016122278A Active JP6385986B2 (ja) | 2010-05-28 | 2016-06-21 | オリゴベンズアミド化合物およびそれらの使用 |
| JP2018097720A Pending JP2018131459A (ja) | 2010-05-28 | 2018-05-22 | オリゴベンズアミド化合物およびそれらの使用 |
Country Status (14)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130115108A (ko) | 2010-05-28 | 2013-10-21 | 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 올리고－벤즈아미드 화합물 및 이의 용도 |
| AU2012273182A1 (en) * | 2011-06-21 | 2014-01-16 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
| WO2013078277A1 (en) | 2011-11-23 | 2013-05-30 | The Board Of Regents Of The University Of Texas System | Oligo-benzamide compounds and their use in treating cancers |
| US8835493B2 (en) | 2011-11-23 | 2014-09-16 | Board Of Regents, The University Of Texas System | Oligo-benzamide compounds for use in treating cancers |
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| CA2984591A1 (en) * | 2015-05-18 | 2016-11-24 | Nerre Therapeutics Limited | Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases |
| CN113384390B (zh) | 2015-09-15 | 2023-08-22 | 萨维奇医疗股份有限公司 | 用于在组织腔中锚定护套的装置和方法 |
| USD874674S1 (en) * | 2016-10-17 | 2020-02-04 | Brandcore Limited | Vibrator |
| CA3121247A1 (en) * | 2018-12-03 | 2020-06-11 | Board Of Regents, The University Of Texas System | Oligo-benzamide analogs and their use in cancer treatment |
| US20250114313A1 (en) * | 2022-02-11 | 2025-04-10 | Board Of Regents, The University Of Texas System | Oligo-benzamide analogs and their use in cancer treatment |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1903899A (en) | 1933-04-18 | Cabboxylic acid abylides oe the benzene sebies and process oe making | ||
| US3951914A (en) | 1974-07-30 | 1976-04-20 | E. I. Du Pont De Nemours And Company | Process for preparing poly(1,4-benzamide) in cyclic sulfone media |
| US5212203A (en) | 1986-01-21 | 1993-05-18 | Centre International De Recherches Dermatogologiques (C.I.R.D.) | Aromatic benzamido compounds; their preparation and their use in human or veterinary medicine or in cosmetic preparations |
| US5734081A (en) | 1994-08-05 | 1998-03-31 | Warner-Lambert Company | Arylthio compounds |
| ES2254385T3 (es) | 2000-02-29 | 2006-06-16 | Millennium Pharmaceuticals, Inc. | Benzamidas e inhibidores relacionados del factor xa. |
| US7355081B2 (en) * | 2002-04-17 | 2008-04-08 | The University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
| AU2004272004B2 (en) * | 2003-09-10 | 2009-01-22 | Merck Sharp & Dohme Corp. | 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
| JP2007528725A (ja) | 2004-02-20 | 2007-10-18 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 結合ペルオキシダーゼ模倣物及びその使用 |
| WO2006086345A2 (en) | 2005-02-07 | 2006-08-17 | The Trustees Of Columbia University In The City Of New York | Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity |
| AU2006311433B2 (en) | 2005-11-08 | 2012-06-28 | Choongwae Pharma Corporation | Alpha-helix mimetics and method relating to the treatment of cancer stem cells |
| WO2008112941A1 (en) * | 2007-03-13 | 2008-09-18 | Board Of Regents The University Of Texas System | Composition and method for the treatment of diseases affected by a peptide receptor |
| US8236983B2 (en) | 2008-03-13 | 2012-08-07 | Board Of Regents, The University Of Texas System | Composition and method for the treatment of diseases affected by apoptosis |
| PE20121470A1 (es) * | 2007-10-26 | 2012-11-18 | Univ California | Compuestos de diarilhidantoina como antagonistas del receptor de androgeno |
| CN104474529A (zh) | 2008-02-08 | 2015-04-01 | 爱勒让治疗公司 | 治疗性的拟肽大环化合物 |
| ES2488990T3 (es) * | 2008-02-22 | 2014-09-01 | Radius Health, Inc. | Moduladores selectivos del receptor de andrógenos |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| CN101643451B (zh) * | 2008-08-07 | 2013-03-06 | 浙江海正药业股份有限公司 | 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法 |
| PL2352508T3 (pl) | 2008-10-17 | 2014-09-30 | Dana Farber Cancer Inst Inc | Peptydy domeny cytoplazmatycznej MUC-1 jako inhibitory nowotworu |
| EP2391372A4 (en) | 2009-01-30 | 2013-07-03 | Bayer Healthcare Llc | ESTROGENIC RECEPTOR-BASED CANCER TREATMENT METHODS BY INHIBITING X1 BOXING BINDING PROTEIN (XBP1) |
| EP2490531A4 (en) | 2009-10-23 | 2013-06-19 | Panacela Labs Inc | METHOD FOR THE TREATMENT OF ANDROGEN RECEPTOR POSITIVE CANCER |
| KR20130115108A (ko) | 2010-05-28 | 2013-10-21 | 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 올리고－벤즈아미드 화합물 및 이의 용도 |
| WO2013078277A1 (en) | 2011-11-23 | 2013-05-30 | The Board Of Regents Of The University Of Texas System | Oligo-benzamide compounds and their use in treating cancers |
| US8835493B2 (en) * | 2011-11-23 | 2014-09-16 | Board Of Regents, The University Of Texas System | Oligo-benzamide compounds for use in treating cancers |
-
2011
- 2011-05-27 KR KR1020127033981A patent/KR20130115108A/ko not_active Withdrawn
- 2011-05-27 EP EP11787517.9A patent/EP2575453B1/en active Active
- 2011-05-27 WO PCT/US2011/038395 patent/WO2011150360A1/en not_active Ceased
- 2011-05-27 BR BR112012030298A patent/BR112012030298A2/pt not_active IP Right Cessation
- 2011-05-27 CN CN2011800323958A patent/CN102958364A/zh active Pending
- 2011-05-27 MX MX2012013855A patent/MX2012013855A/es not_active Application Discontinuation
- 2011-05-27 US US13/700,500 patent/US20130231385A1/en not_active Abandoned
- 2011-05-27 CA CA2800811A patent/CA2800811C/en active Active
- 2011-05-27 AU AU2011258009A patent/AU2011258009B2/en active Active
- 2011-05-27 JP JP2013512048A patent/JP2013528174A/ja active Pending
- 2011-05-27 EA EA201291460A patent/EA201291460A1/ru unknown
- 2011-05-27 SG SG2012087235A patent/SG186076A1/en unknown
-
2012
- 2012-11-27 CL CL2012003322A patent/CL2012003322A1/es unknown
- 2012-12-04 CO CO12219956A patent/CO6640301A2/es not_active Application Discontinuation
-
2015
- 2015-11-04 US US14/932,480 patent/US9856206B2/en active Active
-
2016
- 2016-06-21 JP JP2016122278A patent/JP6385986B2/ja active Active
-
2018
- 2018-01-02 US US15/860,095 patent/US10618869B2/en active Active
- 2018-05-22 JP JP2018097720A patent/JP2018131459A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013528174A5 (cg-RX-API-DMAC7.html) | ||
| DK2326329T3 (en) | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine | |
| JP2019510832A5 (cg-RX-API-DMAC7.html) | ||
| KR101848131B1 (ko) | 저용량 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| KR20180105685A (ko) | 투카레솔 또는 이의 유사체를 함유하는 조성물 | |
| US12213978B2 (en) | Madrasin-derivative compounds, composition and uses thereof for treating cancer | |
| JP5976923B2 (ja) | イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| US11110105B2 (en) | Compounds, composition and uses thereof for treating cancer | |
| US20150110864A1 (en) | Novel antitumor agent comprising combination of three agents | |
| HK40113079A (en) | Antineoplastic combinations of neratinib and capecitabine | |
| JP2015199678A (ja) | ラパチニブトシル酸塩水和物を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
| HK1239521B (en) | Antineoplastic combinations of neratinib and capecitabine | |
| HK1239521A1 (en) | Antineoplastic combinations of neratinib and capecitabine | |
| TH1901007379A (th) | ตัวยับยั้ง kras g12c และวิธีการใช้สิ่งดังกล่าว | |
| NZ740252B2 (en) | Antitumor agent including low-dose irinotecan hydrochloride hydrate | |
| JP2015199677A (ja) | ノギテカン塩酸塩を含有する抗腫瘍剤及び抗腫瘍効果増強剤 |